Mats H.
- Country
- Sweden
- Department
- Blood and tumor diseases
Research Overview
- Phase II Study of ME-401 with Rituximab-Bendamustine for High-Risk and Rituximab with ME-401 Randomization for Low-Risk Follicular Lymphoma Treatment
- Biomarker-Driven Targeted Therapy in Advanced Cancer: A Swedish Nationwide Clinical Trial (FOCU.SE)
- Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)
Data & Insights
Has run more than one trial at 48 of 172 partner sites.
Specializations
Lymphoma Research Focus
This investigator specializes in treating various forms of B-cell lymphomas, with particular emphasis on follicular lymphoma and diffuse large B-cell lymphoma.
- B-cell Non-Hodgkin Lymphoma
- Marginal Zone Lymphoma
- High-risk and Low-risk Follicular Lymphoma
Treatment Approaches
The investigator explores innovative therapeutic combinations involving targeted immunotherapies and established treatment protocols. Their work includes evaluating novel agents such as epcoritamab, mosunetuzumab, and tafasitamab.
- Combination Therapy Development
- Immunotherapy Applications
- Treatment Response Assessment
Clinical Focus Areas
Specializes in managing both newly diagnosed and relapsed/refractory lymphomas, with particular attention to developing treatments for patients with early disease progression.
- Primary Treatment Strategies
- Second-line Therapy Development
- High-risk Disease Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.